Welcome to our dedicated page for Actinium Pharmac news (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmac stock.
The Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) news page on Stock Titan aggregates company announcements, scientific conference updates and regulatory disclosures related to its Actinium-225 targeted radiotherapy programs. Actinium regularly issues press releases detailing preclinical and clinical data, corporate events and participation in oncology meetings, offering investors and observers insight into the evolution of its pipeline.
Recent news has focused heavily on ATNM-400, the company’s first-in-class, multi-indication Ac-225 antibody radioconjugate. Actinium has reported preclinical data for ATNM-400 in metastatic castration-resistant prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer, including models resistant to standard-of-care therapies such as enzalutamide, 177Lu-PSMA-617, osimertinib, tamoxifen and trastuzumab. Releases describe superior tumor growth inhibition versus several approved agents, durable tumor control, and synergistic effects when ATNM-400 is combined with ARPIs or EGFR inhibitors.
News items also cover Actimab-A, a CD33-targeting Ac-225 therapeutic for acute myeloid leukemia, including its planned pivotal Phase 2/3 trial and a Cooperative Research and Development Agreement with the National Cancer Institute. Additional updates describe Iomab-ACT and Iomab-B in conditioning for bone marrow transplant and cell or gene therapies, as well as Actinium’s broader research efforts in solid tumors.
Visitors to this page can review earnings‑independent scientific updates, conference abstracts and corporate communications that outline Actinium’s development strategy, preclinical results and governance milestones such as annual meeting outcomes. For anyone tracking ATNM as an oncology development story, this news feed provides a centralized view of how the company portrays progress across its Ac‑225 radiotherapy platform.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced promising safety data from its pivotal Phase 3 SIERRA trial of Iomab-B for treating relapsed or refractory Acute Myeloid Leukemia (R/R AML), presented at the 2020 ASH annual meeting. Data from 110 patients indicated that Iomab-B significantly reduces the rates of sepsis, febrile neutropenia, mucositis, and non-relapse transplant-related mortality compared to traditional therapies. Actinium remains optimistic about Iomab-B's effectiveness leading into the upcoming ad hoc interim analysis for SIERRA, with 75% patient enrollment.
Actinium Pharmaceuticals (NYSE: ATNM) announced interim results from its Actimab-A CLAG-M Phase 1 trial for relapsed/refractory Acute Myeloid Leukemia (AML) at the ASH annual meeting. In the third dose cohort, 100% of evaluable patients achieved remission. Overall, 67% of patients across the first three cohorts attained Complete Remission (CR) or Complete Remission with incomplete hematopoietic recovery (CRi). Furthermore, 83% of patients with three or fewer prior treatments achieved CR/CRi, with 70% of these patients being MRD negative. The trial is moving to a fourth cohort with a higher dose.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has appointed Mary Mei Chen, M.D., Ph.D., as Vice President of Clinical Development effective immediately. Dr. Chen will oversee the clinical development of Actinium's CD33 program, including combination trials involving Actimab-A in relapsed and refractory Acute Myeloid Leukemia (R/R AML). With over 20 years of experience, including pivotal Phase 3 trials, Dr. Chen aims to advance targeted radiotherapy approaches to improve R&D efforts for better patient outcomes in AML and other hematologic malignancies.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced significant advancements in its intellectual property portfolio for apamistamab, a CD45 targeting antibody, and the Antibody Radiation Conjugate (ARC) linked with iodine-131. The company holds patents protecting its core products, notably Iomab-B, until 2037 in the US and until 2036 in Europe, which bolsters its market position. Iomab-B is currently under investigation in the Phase 3 SIERRA trial for treating relapsed or refractory Acute Myeloid Leukemia, with over 75% enrollment. Actinium aims to improve patient outcomes by minimizing the side effects of traditional chemotherapy in conditioning protocols.
Actinium Pharmaceuticals (NYSE: ATNM) has appointed Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs. Dr. Desai will lead medical affairs for Iomab-B and Actimab-A and contribute to strategic development of Iomab-B's clinical programs. His extensive experience in hematology and oncology, including successful product launches at GSK, positions him well for this role. The company looks to advance clinical trials, particularly the SIERRA trial for Iomab-B, which is in its final phases, enhancing its potential market impact.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will participate in the Alliance Global Partners' Virtual Healthcare Symposium on November 19, 2020. Chief Medical Officer Mark Berger will discuss trends in hematology ahead of the American Society of Hematology (ASH) Annual Meeting in December. Actinium's Antibody Radiation Conjugates, Iomab-B and Actimab-A, will feature in various presentations at ASH. The pivotal Phase 3 SIERRA trial for Iomab-B has over 75% enrollment, showcasing promising data. For one-on-one investor meetings, contact Clayton Robertson.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will host a CD33 program update event featuring key opinion leaders on November 11, 2020, at 4:15 PM ET. Dr. Ehab Atallah will present data from the Actimab-A CLAG-M trial, revealing a 100% remission rate in its final dose cohort. Dr. Gary Schiller will discuss the Actimab-A venetoclax trial, emphasizing the lack of options for relapsed or refractory acute myeloid leukemia (R/R AML). Both trials have promising results and will be discussed further at the upcoming ASH Annual Meeting.
Actinium Pharmaceuticals (NYSE: ATNM) announced that 100% of evaluable patients in the third dose cohort of the Actimab-A CLAG-M Phase 1 trial achieved remission. Overall, 67% of patients across three cohorts reached either Complete Remission (CR) or Complete Remission with inadequate hematopoietic recovery (CRi). Notably, 70% of CR/CRi patients were MRD negative, showing no detectable disease. With an acceptable safety profile, a fourth dose cohort is now being explored. Results will be presented at the ASH annual meeting on December 5, 2020.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced two oral presentations on its Antibody Radiation Conjugate, Iomab-B, at the 2020 ASH annual meeting from December 5-8. The presentations will highlight findings from the Phase 3 SIERRA trial, focusing on Iomab-B for treating relapsed or refractory Acute Myeloid Leukemia (R/R AML). The trial shows promising results with 100% engraftment in the treatment arm and significant treatment failures in the control arm, indicating a critical need for new therapies. Safety and feasibility data from 75% of patients are expected later this quarter.
Actinium Pharmaceuticals (NYSE: ATNM) has announced the acceptance of data from its Phase 1 trial of the Actimab-A and venetoclax combination for presentation at the 2020 ASH annual meeting, taking place virtually from December 5-8, 2020. The trial showed an acceptable safety profile and a partial response in patients with relapsed/refractory acute myeloid leukemia (R/R AML) after one treatment cycle. The trial will continue to assess the combination's efficacy, with encouraging initial results suggesting potential therapeutic synergy.
FAQ
What is the current stock price of Actinium Pharmac (ATNM)?
What is the market cap of Actinium Pharmac (ATNM)?
